Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective-Reference-Cited by-同舟云学术

Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective

Published:2022-04-25 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Xi Xiaoyu,Wang Xin,Xie Wenwen,Jia Yu,Sanchez Santiago Zuluaga,Martinez Laura,Zhao Quanming^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10557-021-07276-x.pdf

Reference37 articles.

1. Huo Y, Han Y, Ge J, et al. Two-year outcomes post discharge in Chinese patients with acute coronary syndrome: findings from the Epicor Asia study [J]. J Am Coll Cardiol. 2016;67(13):505.

2. Cholesterol TT. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet Lond. 2012.

3. Howard WJ. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins [J]. Yearb Med. 2007;2007:515–6.

4. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? [J]. BMJ Clin Res. 1994;308(6925):367–72.

5. Larosa J, Grundy S, Waters D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med. 2005;352(14):1425–35.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review;Current Therapeutic Research;2024-09

2. PCSK9 inhibition: from effectiveness to cost-effectiveness;Frontiers in Cardiovascular Medicine;2024-06-25

3. Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China;Cost Effectiveness and Resource Allocation;2023-12-01

4. The 10 essential questions regarding lipoprotein(a);Current Opinion in Clinical Nutrition & Metabolic Care;2023-11-15

5. A Practical Statin Recommendation System Based on Real-World Data to Improve LDL-C Management in Secondary Prevention;Journal of Cardiovascular Pharmacology;2023-05